Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, has announced its upcoming participation in a virtual event. CEO Marcio Souza will engage in a fireside chat hosted by Truist Securities analyst Joon Lee on August 5, 2025 at 10:00 AM EST.
Praxis Precision Medicines (NASDAQ: PRAX), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie per disturbi del sistema nervoso centrale, ha annunciato la sua prossima partecipazione a un evento virtuale. Il CEO Marcio Souza parteciperĆ a una conversazione informale moderata dall'analista di Truist Securities Joon Lee il 5 agosto 2025 alle 10:00 EST.
Praxis Precision Medicines (NASDAQ: PRAX), una compaƱĆa biofarmacĆ©utica en etapa clĆnica enfocada en desarrollar terapias para trastornos del sistema nervioso central, ha anunciado su prĆ³xima participaciĆ³n en un evento virtual. El CEO Marcio Souza participarĆ” en una charla informal moderada por el analista de Truist Securities Joon Lee el 5 de agosto de 2025 a las 10:00 AM EST.
Praxis Precision Medicines (NASDAQ: PRAX)µē� ģ¤ģ¶ģ ź²½ź³� ģ§ķ ģ¹ė£ģ � ź°ė°ģ� ģ£¼ė „ķµē ģģ ėØź³ ė°ģ“ģ¤ģ ģ� ķģ¬ė”�, ź³� ź°ģµėµē ź°ģ� ķģ¬ģ� ģ°øģ¬ķ� ģģ ģģ ė°ķķģµėė¤. CEO Marcio Souzaµē� Truist Securitiesģ� ģ ėė¦¬ģ¤ķ� Joon Leeź° ģ§ķķµē ėķģ 2025ė � 8ģ� 5ģ� ģ¤ģ 10ģ� ESTģ� ģ°øģ¬ķ� ģģ ģ ėė�.
Praxis Precision Medicines (NASDAQ : PRAX), une sociĆ©tĆ© biopharmaceutique en phase clinique spĆ©cialisĆ©e dans le dĆ©veloppement de thĆ©rapies pour les troubles du systĆØme nerveux central, a annoncĆ© sa prochaine participation Ć un Ć©vĆ©nement virtuel. Le PDG Marcio Souza participera Ć une discussion informelle animĆ©e par lāanalyste de Truist Securities Joon Lee le 5 aoĆ»t 2025 Ć 10h00 EST.
Praxis Precision Medicines (NASDAQ: PRAX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien fĆ¼r Erkrankungen des zentralen Nervensystems konzentriert, hat seine bevorstehende Teilnahme an einer virtuellen Veranstaltung angekĆ¼ndigt. CEO Marcio Souza wird an einem GesprƤch mit Truist Securities Analyst Joon Lee am 5. August 2025 um 10:00 Uhr EST teilnehmen.
- None.
- None.
BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Truist Securities analyst Joon Lee on August 5, 2025 at 10:00amEST.
The registration link can be found .
About PraxisāÆĀ�
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrumā�, and antisense oligonucleotide (ASO) platform, Solidusā�, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visitĀ Ā and follow us onĀ ,Ģż,ĢżĢż²¹²Ō»åĢż.
Investor Contact:Ā Praxis Precision MedicinesĀ [email protected]Ā 857-702-9452Ā Media Contact: Dan Ferry Life Science Advisors [email protected] 617-430-7576
FAQ
When is the Praxis Precision Medicines (PRAX) fireside chat scheduled for?
Who will represent Praxis Precision Medicines at the Truist Securities fireside chat?
What is Praxis Precision Medicines' (PRAX) main focus area?
Who is hosting the PRAX fireside chat?
